Discovery of GPCR ligands for probing signal transduction pathways

Frontiers in Pharmacology

Volumn 5, Issue NOV, 2014, Pages

  Brogi, Simone ^a   Tafi, Andrea ^a   Désaubry, Laurent ^b   Nebigil, Canan G ^b  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

Allosteric modulators; Biased agonists; Biased signaling; Bivalent ligands; G protein coupled receptors; GPCR; High throughput docking; Homology modeling

Indexed keywords

ANGIOTENSIN RECEPTOR; ARIPIPRAZOLE; AZETIDINONE DERIVATIVE; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID 2 RECEPTOR; CARVEDILOL; CINACALCET; DOPAMINE RECEPTOR; ENDOTHELIN RECEPTOR; G PROTEIN COUPLED RECEPTOR; MARAVIROC; MORPHINE; MU OPIATE RECEPTOR AGONIST; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; MUSCARINIC M4 RECEPTOR; MUSCARINIC M5 RECEPTOR; MUSCARINIC RECEPTOR; NALTRINDOLE; OPIATE RECEPTOR; PLERIXAFOR; RHODOPSIN; RIMONABANT; SUMATRIPTAN; TRV 130; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADDICTION; ALLOSTERISM; BINDING AFFINITY; BINDING SITE; CHRONIC PAIN; COMPUTER MODEL; DRUG DESIGN; DRUG DETERMINATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCALCEMIA; HYPERPARATHYROIDISM; LIGAND BINDING; METABOLIC DISORDER; MISSENSE MUTATION; MOLECULAR DOCKING; NEUROLOGIC DISEASE; NONHUMAN; OBESITY; PAIN; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; UNSPECIFIED SIDE EFFECT;

EID: 84910610083     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2014.00255     Document Type: Review

References (137)

1. Abagyan, R., and Totrov, M. (2001). High-throughput docking for lead generation. Curr Opin Chem Biol 5, 375-382.
2. Abbas, A., and Roth, B.L. (2008). Arresting serotonin. Proc Natl Acad Sci USA 105, 831-832. doi: 10.1073/pnas.0711335105.
3. Abreu, A.P., Noel, S.D., Xu, S., Carroll, R.S., Latronico, A.C., and Kaiser, U.B. (2012). Evidence of the importance of the first intracellular loop of prokineticin receptor 2 in receptor function. Mol Endocrinol 26,1417-1427. doi: 10.1210/me.2012-1102 me.2012-1102 [pii].
4. Agelis, G., Resvani, A., Koukoulitsa, C, Tumova, T., Slaninova, J., Kalavrizioti, D., Spyridaki, K., Afantitis, A., Melagraki, G., Siafaka, A., Gkini, E., Megariotis, G., Grdadolnik, S.G., Papadopoulos, M.G., Vlahakos, D., Maragoudakis, M., Liapakis, G., Mavromoustakos, T., and Matsoukas, J. (2013). Rational design, efficient syntheses and biological evaluation of N, N'-symmetrically bis-substituted butylimidazole analogs as a new class of potent Angiotensin II receptor blockers. Eur J Med Chem 62, 352-370. doi: 10.1016/j.ejmech.2012.12.044.
5. Allen, J.A., and Roth, B.L. (2011). Strategies to discover unexpected targets for drugs active at G protein-coupled receptors. Annu Rev Pharmacol Toxicol 51, 117-144. doi: 10.1146/annurev-pharmtox-010510-100553.
6. Anastassopoulos, K.P., Chow, W., Ackerman, S.J., Tapia, C, Benson, C, and Kim, M.S. (2011). Oxycodone-related side effects: impact on degree of bother, adherence, pain relief, satisfaction, and quality of life./Opioid Manag 7, 203-215.
7. Andrews, S.P., Brown, G.A., and Christopher, J.A. (2014). Structure-based and fragmentbased GPCR drug discovery. Chem Med Chem 9, 256-275. doi: 10.1002/cmdc.201300382.
8. Armbruster, B.N., Li, X., Pausch, M.H., Herlitze, S., and Roth, B.L. (2007). Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand. Proc Natl Acad Sci USA 104, 5163-5168. doi: 0700293104 [pii] 10.1073/pnas.0700293104.
9. Beaulieu, J.M., and Gainetdinov, R.R. (2011). The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev 63,182-217. doi: 10.1124/pr.ll0.002642.
10. Beaulieu, J.M., Sotnikova, T.D., Marion, S., Lefkowitz, R.J., Gainetdinov, R.R., and Caron, M.G. (2005). An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 122, 261-273. doi: 10.1016/j.cell.2005.05.012.
11. Benigni, A., Cassis, P., and Remuzzi, G. (2010). Angiotensin II revisited: new roles in inflammation, immunology and aging. EMBO Mol Med 2, 247-257. doi: 10.1002/emmm.201000080.
12. Brissac, T., Mikaty, G., Dumenil, G., Coureuil, M., and Nassif, X. (2012). The meningococcal minor pilin PilX is responsible for type IV pilus conformational changes associated with signaling to endothelial cells. Infect Immun 80, 3297-3306. doi: 10.1128/IAI.00369-12.
13. Brogi, S., Corelli, F., Di Marzo, V., Ligresti, A., Mugnaini, C, Pasquini, S., and Tafi, A. (2011). Three-dimensional quantitative structure-selectivity relationships analysis guided rational design of a highly selective ligand for the cannabinoid receptor 2. EurJ Med Chem 46, 547-555. doi: 10.1016/j.ejmech.2010.11.034.
14. Brogi, S., Kladi, M., Vagias, C, Papazafiri, P., Roussis, V., and Tafi, A. (2009). Pharmacophore modeling for qualitative prediction of antiestrogenic activity./Chem Inf Model 49, 2489-2497. doi: 10.1021/ci900254b.
15. Brogi, S., Papazafiri, P., Roussis, V., and Tafi, A. (2013). 3D-QSAR using pharmacophorebased alignment and virtual screening for discovery of novel MCF-7 cell line inhibitors. EurJ Med Chem 67, 344-351. doi: 10.1016/j.ejmech.2013.06.048.
16. Bruchas, M.R., Land, B.B., and Chavkin, C. (2010). The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors. Brain Res 1314, 44-55. doi: 10.1016/j.brainres.2009.08.062
17. Burford, N.T., Watson, J., Bertekap, R., and Alt, A. (2011). Strategies for the identification of allosteric modulators of G-protein-coupled receptors. Biochem Pharmacol 81, 691-702. doi: 10.1016/j.bcp.2010.12.012.
18. Burford, N.T., Clark, M.J., Wehrman, T.S., Gerritz, S.W., Banks, M., O'Connell, J, Traynor, J.R., and Alt, A. (2013). Discovery of positive allosteric modulators and silent allosteric modulators of μ-opioid receptor. Proc Natl Acad Sci USA. 110, 10830-5. doi: 10.1073/pnas. 1300393110.
19. Cappelli, A., Manini, M., Valenti, S., Castriconi, F., Giuliani, G., Anzini, M., Brogi, S., Butini, S., Gemma, S., Campiani, G., Giorgi, G., Mennuni, L, Lanza, M., Giordani, A., Caselli, G., Letari, 0., and Makovec, F. (2013). Synthesis and structure-activity relationship studies in serotonin 5-HT(lA) receptor agonists based on fused pyrrolidone scaffolds. EurJ Med Chem 63, 85-94. doi: 10.1016/j.ejmech.2013.01.044.
20. Castelli, M.P., Casu, A., Casti, P., Lobina, C, Carai, M.A., Colombo, G., Solinas, M., Giunta, D., Mugnaini, C, Pasquini, S., Tafi, A., Brogi, S., Gessa, G.L., and Corelli, F. (2012). Characterization of COR627 and COR628, two novel positive allosteric modulators of the GABA(B) receptor./Pharmacol Exp Ther 340, 529-538. doi: 10.1124/jpet.lll.l86460.
21. Chen, X.T., Pitis, P., Liu, G., Yuan, C, Gotchev, D., Cowan, C.L., Rominger, D.H., Koblish, M., Dewire, S.M., Crombie, A.L., Violin, J.D., and Yamashita, D.S. (2013). Structure-activity relationships and discovery of a G protein biased mu opioid receptor ligand, [(3-methoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro-[4.5]decan- 9-yl]ethylJ)amine (TRV130), for the treatment of acute severe pain./Med Chem 56, 8019-8031. doi: 10.1021/jm4010829.
22. Cherezov, V., Peddi, A., Muthusubramaniam, L., Zheng, Y.F., and Caffrey, M. (2004). A robotic system for crystallizing membrane and soluble proteins in lipidic mesophases. Acta Crystallogr D Biol Crystallogr 60,1795-1807. doi: 10.1107/S0907444904019109
23. Cherezov, V., Rosenbaum, D.M., Hanson, MA, Rasmussen, S.G., Thian, F.S., Kobilka, T.S., Choi, H.J., Kuhn, P., Weis, W.I., Kobilka, B.K., and Stevens, R.C. (2007). High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 318,1258-1265. doi: 10.1126/science.ll50577.
24. Chien, E.Y., Liu, W., Zhao, Q., Katritch, V., Han, G.W., Hanson, M.A., Shi, L, Newman, A.H., Javitch, J.A., Cherezov, V., and Stevens, R.C. (2010). Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science 330, 1091-1095. doi: 10.1126/science.ll97410.
25. Christopher, J.A., Brown, J., Dore, A.S., Errey, J.C., Koglin, M., Marshall, F.H., Myszka, D.G., Rich, R.L., Tate, C.G., Tehan, B., Warne, T., and Congreve, M. (2013). Biophysical fragment screening of the betal-adrenergic receptor: identification of high affinity arylpiperazine leads using structure-based drug design. J Med Chem 56, 3446-3455. doi: 10.1021/jm400140q.
26. Christopoulos, A. (2002). Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nat Rev Drug Discov 1,198-210. doi: 10.1038/nrd746.
27. Chun, E., Thompson, A.A., Liu, W., Roth, C.B., Griffith, M.T., Katritch, V., Kunken, J., Xu, F., Cherezov, V., Hanson, M.A., and Stevens, R.C. (2012). Fusion partner toolchest for the stabilization and crystallization of G protein-coupled receptors. Structure 20, 967-976. doi: 10.1016/j.str.2012.04.010.
28. Dahan, A. (2007). Respiratory depression with opioids. J Pain Palliat Care Pharmacother 21, 63-66.
29. Daniels, D.J., Lenard, N.R., Etienne, C.L., Law, P.Y., Roerig, S.C., and Portoghese, P.S. (2005). Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series. Proc Natl Acad Sci USA 102, 19208-19213. doi: 10.1073/pnas.0506627102.
30. Dewire, S.M., Ahn, S., Lefkowitz, R.J., and Shenoy, S.K. (2007). Beta-arrestins and cell signaling. Annu Rev Physiol 69, 483-510. doi: 10.1146/annurev.ph.69.013107.100021.
31. Dewire, S.M., and Violin, J.D. (2011). Biased ligands for better cardiovascular drugs: dissecting G-protein-coupled receptor pharmacology. Circ Res 109, 205-216. doi: 10.1161/CIRCRESAHA.110.231308109/2/205 [pii].
32. Di Marzo, V. (2008). Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discov 7, 438-455. doi: 10.1038/nrd2553.
33. Dore, A.S., Okrasa, K., Patel, J.C., Serrano-Vega, M., Bennett, K., Cooke, R.M., Errey, J.C., Jazayeri, A., Khan, S., Tehan, B., Weir, M., Wiggin, G.R., and Marshall, F.H. (2014). Structure of class C GPCR metabotropic glutamate receptor 5 transmembrane domain. Nature 511, 557-562. doi: 10.1038/naturel3396.
34. Dormishian, M., Turkeri, G., Urayama, K., Nguyen, T.L., Boulberdaa, M., Messaddeq, N., Renault, G., Henrion, D., and Nebigil, C.G. (2013). Prokineticin receptor-1 is a new regulator of endothelial insulin uptake and capillary formation to control insulin sensitivity and cardiovascular and kidney functions./Am Heart Assoc 2, e000411. doi: 10.1161/JAHA.113.000411 jah3343 [pii].
35. Fatkenheuer, G., Pozniak, A.L., Johnson, M.A., Plettenberg, A., Staszewski, S., Hoepelman, A.I., Saag, M.S., Goebel, F.D., Rockstroh, J.K., Dezube, B.J., Jenkins, T.M., Medhurst, C, Sullivan, J.F., Ridgway, C, Abel, S., James, I.T., Youle, M., and Van Der Ryst, E. (2005). Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 11,1170-1172. doi: 10.1038/nml319.
36. Fenalti, G., Giguere, P.M., Katritch, V., Huang, X.P., Thompson, A.A., Cherezov, V., Roth, B.L., and Stevens, R.C. (2014). Molecular control of delta-opioid receptor signalling. Nature 506,191-196. doi: 10.1038/naturel2944.
37. Fernandez-Fuentes, N., Rai, B.K., Madrid-Aliste, C.J., Fajardo, J.E., and Fiser, A. (2007). Comparative protein structure modeling by combining multiple templates and optimizing sequence-to-structure alignments. Bioinformatics 23, 2558-2565. doi: btm377 [pii] 10.1093/bioinformatics/btm377.
38. Funk, O.F., Kettmann, V., Drimal, J., and Langer, T. (2004). Chemical function based pharmacophore generation of endothelin-A selective receptor antagonists./Med Chem 47, 2750-2760. doi: 10.1021/jm031041j.
39. Garner, A.R., Rowland, D.C., Hwang, S.Y., Baumgaertel, K., Roth, B.L., Kentros, C, and Mayford, M. (2012). Generation of a synthetic memory trace. Science 335, 1513-1516. doi: 10.1126/science.l214985335/6075/1513 [pii].
40. Gemma, S., Brogi, S., Novellino, E., Campiani, G., Maga, G., Brindisi, M., and Butini, S. (2014a). HCV-targeted antivirals: current status and future challenges. Curr Pharm Des 20, 3445-3464.
41. Gemma, S., Brogi, S., Patil, P.R., Giovani, S., Lamponi, S., Cappelli, A., Novellino, E., Brown, A., Higgins, M.K., Mustafa, K., Szestak, T., Craig, A.G., Campiani, G., Butini, S., and Brindisi, M. (2014b). From (+)-epigallocatechin gallate to a simplified synthetic analogue as a cytoadherence inhibitor for P. falciparum. RSC Advances 4, 4769-4781. doi: 10.1039/c3ra45933k.
42. Gesty-Palmer, D., Flannery, P., Yuan, L, Corsino, L, Spurney, R., Lefkowitz, R.J., and Luttrell, L.M. (2009). A beta-arrestin-biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation. Sci Transl Med 1, l r a l. doi: 10.1126/scitranslmed.3000071.
43. Giovani, S., Penzo, M., Brogi, S., Brindisi, M., Gemma, S., Novellino, E., Savini, L, Blackman, M.J., Campiani, G., and Butini, S. (2014). Rational design of the first difluorostatonebased PfSUBl inhibitors. Bioorg Med Chem Lett 24, 3582-3586. doi: 10.1016/j.bmcl.2014.05.044.
44. Goodfriend, T.L., Elliott, M.E., and Catt, K.J. (1996). Angiotensin receptors and their antagonists. NEnglJMed 334,1649-1654. doi: 10.1056/NEJM199606203342507.
45. Granier, S., Manglik, A., Kruse, A.C., Kobilka, T.S., Thian, F.S., Weis, W.I., and Kobilka, B.K. (2012). Structure of the delta-opioid receptor bound to naltrindole. Nature 485, 400-404. doi: 10.1038/naturelllll.
46. Grasberger, H., Van Sande, J., Hag-Dahood Mahameed, A., Tenenbaum-Rakover, Y., and Refetoff, S. (2007). A familial thyrotropin (TSH) receptor mutation provides in vivo evidence that the inositol phosphates/Ca2+ cascade mediates TSH action on thyroid hormone synthesis./Clin Endocrinol Metab 92, 2816-2820. doi: jc.2007-0366 [pii] 10.1210/JC.2007-0366.
47. Guettier, J.M., Gautam, D., Scarselli, M., Ruiz De Azua, I., Li, J.H., Rosemond, E., Ma, X., Gonzalez, F.J., Armbruster, B.N., Lu, H., Roth, B.L., and Wess, J. (2009). A chemical-genetic approach to study G protein regulation of beta cell function in vivo. Proc Natl Acad Sci USA 106, 19197-19202. doi: 10.1073/pnas.0906593106 0906593106 [pii].
48. Haga, K., Kruse, A.C., Asada, H., Yurugi-Kobayashi, T., Shiroishi, M., Zhang, C, Weis, W.I., Okada, T., Kobilka, B.K., Haga, T., and Kobayashi, T. (2012). Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist. Nature 482, 547-551. doi: 10.1038/naturel0753.
49. Hanson, M.A., Cherezov, V., Griffith, M.T., Roth, C.B., Jaakola, V.P., Chien, E.Y., Velasquez, J., Kuhn, P., and Stevens, R.C. (2008). A specific cholesterol binding site is established by the 2.8 A structure of the human beta2-adrenergic receptor. Structure 16, 897-905. doi: 10.1016/j.str.2008.05.001.
50. Hanson, M.A., Roth, C.B., Jo, E., Griffith, M.T., Scott, F.L., Reinhart, G., Desale, H., Clemons, B., Cahalan, S.M., Schuerer, S.C., Sanna, M.G., Han, G.W., Kuhn, P., Rosen, H., and Stevens, R.C. (2012). Crystal structure of a lipid G protein-coupled receptor. Science 335, 851-855. doi: 10.1126/science.l215904.
51. Hollenstein, K., Kean, J., Bortolato, A., Cheng, R.K., Dore, A.S., Jazayeri, A., Cooke, R.M., Weir, M., and Marshall, F.H. (2013). Structure of class B GPCR corticotropin-releasing factor receptor 1. Nature 499, 438-443. doi: 10.1038/naturel2357.
52. Jaakola, V.P., Griffith, M.T., Hanson, M.A., Cherezov, V., Chien, E.Y., Lane, J.R., Ijzerman, A.P., and Stevens, R.C. (2008). The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science 322, 1211-1217. doi: 10.1126/science.ll64772.
53. Khoury, E., Clement, S., and Laporte, S.A. (2014). Allosteric and biased g protein-coupled receptor signaling regulation: potentials for new therapeutics. Front Endocrinol (Lausanne) 5, 68. doi: 10.3389/fendo.2014.00068.
54. Kolb, P., Rosenbaum, D.M., Irwin, J.J., Fung, J.J., Kobilka, B.K., and Shoichet, B.K. (2009). Structure-based discovery of beta2-adrenergic receptor ligands. Proc Natl Acad Sci U SA 106, 6843-6848. doi: 10.1073/pnas.0812657106.
55. Kong, D., Tong, Q., Ye, C, Koda, S., Fuller, P.M., Krashes, M.J., Vong, L, Ray, R.S., Olson, D.P., and Lowell, B.B. (2012). GABAergic RIP-Cre neurons in the arcuate nucleus selectively regulate energy expenditure. Cell 151, 645-657. doi: 10.1016/j.cell.2012.09.020 S0092-8674(12)01127-0 [pii].
56. Kooistra, A.J., Roumen, L., Leurs, R., De Esch, I.J., and De Graaf, C. (2013). From heptahelical bundle to hits from the Haystack: structure-based virtual screening for GPCR ligands. Methods Enzymol 522, 279-336. doi: 10.1016/B978-0-12-407865-9.00015-7.
57. Kopecky, S.L. (2006). Effect of beta blockers, particularly carvedilol, on reducing the risk of events after acute myocardial infarction. Am] Cardiol 98, 1115-1119. doi: S0002-9149(06)01295-1 [pii] 10.1016/j.amjcard.2006.05.039.
58. Kruse, A.C., Hu, J., Pan, A.C., Arlow, D.H., Rosenbaum, D.M., Rosemond, E., Green, H.F., Liu, T., Chae, P.S., Dror, R.O., Shaw, D.E., Weis, W.I., Wess, J., and Kobilka, B.K. (2012). Structure and dynamics of the M3 muscarinic acetylcholine receptor. Nature 482, 552-556. doi: 10.1038/naturel0867.
59. Kruse, A.C., Weiss, D.R., Rossi, M., Hu, J., Hu, K., Eitel, K., Gmeiner, P., Wess, J., Kobilka, B.K., and Shoichet, B.K. (2013). Muscarinic receptors as model targets and antitargets for structure-based ligand discovery. Mol Pharmacol 84, 528-540. doi: 10.1124/mol.ll3.087551.
60. Lane, J.R., Chubukov, P., Liu, W., Canals, M., Cherezov, V., Abagyan, R., Stevens, R.C., and Katritch, V. (2013). Structure-based ligand discovery targeting orthosteric and allosteric pockets of dopamine receptors. Mol Pharmacol 84, 794-807. doi: 10.1124/mol.ll3.088054.
61. Leach, K., Wen, A., Davey, A.E., Sexton, P.M., Conigrave, A.D., and Christopoulos, A. (2012). Identification of molecular phenotypes and biased signaling induced by naturally occurring mutations of the human calcium-sensing receptor. Endocrinology 153, 4304-4316. doi: 10.1210/en.2012-1449 en.2012-1449 [pii].
62. Lefkowitz, R.J., and Shenoy, S.K. (2005). Transduction of receptor signals by beta-arrestins. Science 308, 512-517. doi: 10.1126/science.ll09237.
63. Li, Y.Y., Hou, T.J., and Goddard, W.A., 3rd (2010). Computational modeling of structurefunction of g protein-coupled receptors with applications for drug design. Curr Med Chem 17,1167-1180.
64. Luttrell, L.M., Ferguson, S.S., Daaka, Y., Miller, W.E., Maudsley, S., Delia Rocca, G.J., Lin, F., Kawakatsu, H., Owada, K., Luttrell, D.K., Caron, M.G., and Lefkowitz, R.J. (1999). Betaarrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. Science 283, 655-661.
65. Mailman, R.B., and Murthy, V. (2010). Third generation antipsychotic drugs: partial agonism or receptor functional selectivity? Curr Pharm Des 16, 488-501. doi: CPD-Richard B. Mailman (Albert Adell) [pii].
66. Manglik, A., Kruse, A.C., Kobilka, T.S., Thian, F.S., Mathiesen, J.M., Sunahara, R.K., Pardo, L, Weis, W.I., Kobilka, B.K., and Granier, S. (2012). Crystal structure of the micro-opioid receptor bound to a morphinan antagonist. Nature 485, 321-326. doi: 10.1038/naturel0954.
67. Masri, B., Salahpour, A., Didriksen, M., Ghisi, V., Beaulieu, J.M., Gainetdinov, R.R., and Caron, M.G. (2008). Antagonism of dopamine D2receptor/beta-arrestin 2 interaction is a common property of clinically effective antipsychotics. Proc Natl Acad Sci USA 105, 13656-13661. doi: 10.1073/pnas.0803522105 0803522105 [pii].
68. Matsuda, LA, Lolait, S.J., Brownstein, M.J., Young, A.C., and Bonner, T.I. (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346, 561-564. doi: 10.1038/346561a0.
69. Meng, T., Wang, J., Peng, H., Fang, G., Li, M., Xiong, B., Xie, X., Zhang, Y., Wang, X., and Shen, J. (2010). Discovery of benzhydrylpiperazine derivatives as CB1 receptor inverse agonists via privileged structure-based approach. EurJ Med Chem 45, 1133-1139. doi: 10.1016/j.ejmech.2009.12.018.
70. Mobarec, J.C., Sanchez, R., and Filizola, M. (2009). Modern homology modeling of G-protein coupled receptors: which structural template to use?/Med Chem 52, 5207-5216. doi: 10.1021/jm9005252.
71. Mohr, K., Schmitz, J., Schrage, R., Trannkle, C, and Holzgrabe, U. (2013). Molecular alliance -From orthosteric and allosteric ligands to dualsteric/bitopic agonists at G protein coupled receptors. Angewandte Chemie - International Edition 52, 508-516.
72. Monasky, M.M., Taglieri, D.M., Henze, M., Warren, CM., Utter, M.S., Soergel, D.G., Violin, J.D., and Solaro, R.J. (2013). The beta-arrestin-biased ligand TRV120023 inhibits angiotensin II-induced cardiac hypertrophy while preserving enhanced myofilament response to calcium. Am J Physiol Heart Circ Physiol 305, H856-866. doi: 10.1152/ajpheart.00327.2013 ajpheart.00327.2013 [pii].
73. Nebigil, C.G. (2009). Prokineticin receptors in cardiovascular function: foe or friend? Trends Cardiovasc Med 19, 55-60. doi: 10.1016/j.tcm.2009.04.007 S1050-1738(09)00065-6 [pii].
74. Negri, A., Rives, M.L., Caspers, M.J., Prisinzano, T.E., Javitch, J.A., and Filizola, M. (2013). Discovery of a novel selective kappa-opioid receptor agonist using crystal structurebased virtual screening./Chem Inf Model 53, 521-526. doi: 10.1021/ci400019t.
75. Nygaard, R., Zou, Y., Dror, R.O., Mildorf, T.J., Arlow, D.H., Manglik, A., Pan, A.C., Liu, C.W., Fung, J.J., Bokoch, M.P., Thian, F.S., Kobilka, T.S., Shaw, D.E., Mueller, L, Prosser, R.S., and Kobilka, B.K. (2013). The dynamic process of beta(2)-adrenergic receptor activation. Cell 152, 532-542. doi: 10.1016/j.cell.2013.01.008 S0092-8674(13)00011-l [pii].
76. Oliveira, L, Costa-Neto, CM., Nakaie, C.R., Schreier, S., Shimuta, S.I., and Paiva, A.C. (2007). The angiotensin II ATI receptor structure-activity correlations in the light of rhodopsin structure. Physiol Rev 87, 565-592. doi: 87/2/565 [pii] 10.1152/physrev.00040.2005.
77. Pal, M., and Paliwal, S. (2012). In silico identification of novel lead compounds with ATI receptor antagonist activity: successful application of chemical database screening protocol. Org Med Chem Lett 2, 7. doi: 10.1186/2191-2858-2-7.
78. Palczewski, K., Kumasaka, T., Hori, T., Behnke, C.A., Motoshima, H., Fox, B.A., Le Trong, I., Teller, D.C, Okada, T., Stenkamp, R.E., Yamamoto, M., and Miyano, M. (2000). Crystal structure of rhodopsin: A G protein-coupled receptor. Science 289, 739-745.
79. Pandey, P., Roy, K.K., Liu, H., Elokely, K.M., Pettaway, S., Cutler, S.J., and Doerksen, R.J. (2014). Search for cannabinoid receptor 1 antagonists using structure-based virtual screening: identification of natural product hits. Planta Med 80, PF11. doi: 10.1055/S-0034-1382589.
80. Park, J.H., Scheerer, P., Hofmann, K.P., Choe, H.W., and Ernst, O.P. (2008). Crystal structure of the ligand-free G-protein-coupled receptor opsin. Nature 454, 183-187. doi: 10.1038/nature07063.
81. Park, S.H., Das, B.B., Casagrande, F., Tian, Y., Nothnagel, H.J., Chu, M., Kiefer, H., Maier, K., De Angelis, A.A., Marassi, F.M., and Opella, S.J. (2012). Structure of the chemokine receptor CXCR1 in phospholipid bilayers. Nature 491, 779-783. doi: 10.1038/naturell580.
82. Pasquini, S., Mugnaini, C, Ligresti, A., Tafi, A., Brogi, S., Falciani, C, Pedani, V., Pesco, N., Guida, F., Luongo, L., Varani, K., Borea, P.A., Maione, S., Di Marzo, V., and Corelli, F. (2012). Design, synthesis, and pharmacological characterization of indol-3-ylacetamides, indol-3-yloxoacetamides, and indol-3-ylcarboxamides: potent and selective CB2 cannabinoid receptor inverse agonists. J Med Chem 55, 5391-5402. doi: 10.1021/jm3003334.
83. Percherancier, Y., Berchiche, Y.A., Slight, I., Volkmer-Engert, R., Tamamura, H., Fujii, N., Bouvier, M., and Heveker, N. (2005). Bioluminescence resonance energy transfer reveals ligand-induced conformational changes in CXCR4 homo- and heterodimers./BiolChem 280, 9895-9903. doi: M411151200 [pii] 10.1074/jbc. M411151200.
84. Perez, M., Pauwels, P.J., Fourrier, C, Chopin, P., Valentin, J.P., John, G.W., Marien, M., and Halazy, S. (1998). Dimerization of sumatriptan as an efficient way to design a potent, centrally and orally active 5-HT1B agonist. Bioorg Med Chem Lett 8, 675-680.
85. Pivonello, R., Ferone, D., Lombardi, G., Colao, A., Lamberts, S.W., and Hofland, L.J. (2007). Novel insights in dopamine receptor physiology. EurJ Endocrinol 156 Suppl 1, S13-21. doi: 10.1530/eje.l.02353.
86. Pollock, D.M., Keith, T.L., and Highsmith, R.F. (1995). Endothelin receptors and calcium signaling. FASEBJ9,1196-1204.
87. Poole-Wilson, PA, Swedberg, K., Cleland, J.G., Di Lenarda, A., Hanrath, P., Komajda, M., Lubsen, J., Lutiger, B., Metra, M., Remme, W.J., Torp-Pedersen, C, Scherhag, A., Skene, A., and Carvedilol or Metoprolol European Trial, I. (2003). Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. lancet 362, 7-13. doi: S0140-6736(03)13800-7 [pii] 10.1016/S0140-6736(03)13800-7.
88. Rajagopal, S., Rajagopal, K., and Lefkowitz, R.J. (2010). Teaching old receptors new tricks: biasing seven-transmembrane receptors. Nat Rev Drug Discov 9, 373-386. doi: 10.1038/nrd3024 nrd3024 [pii].
89. Rashid, A.J., O'dowd, B.F., Verma, V., and George, S.R. (2007). Neuronal Gq/11-coupled dopamine receptors: an uncharted role for dopamine. Trends Pharmacol Sci 28, 551-555. doi: 10.1016/j.tips.2007.10.001.
90. Rasmussen, S.G., Choi, H.J., Rosenbaum, D.M., Kobilka, T.S., Thian, F.S., Edwards, P.C., Burghammer, M., Ratnala, V.R., Sanishvili, R., Fischetti, R.F., Schertler, G.F., Weis, W.I., and Kobilka, B.K. (2007). Crystal structure of the human beta2 adrenergic G-proteincoupled receptor. Nature 450, 383-387. doi: 10.1038/nature06325.
91. Renault, N., Laurent, X., Farce, A., El Bakali, J., Mansouri, R., Gervois, P., Millet, R., Desreumaux, P., Furman, C, and Chavatte, P. (2013). Virtual screening of CB(2) receptor agonists from bayesian network and high-throughput docking: structural insights into agonist-modulated GPCR features. Chem Biol Drug Des 81, 442-454. doi: 10.1111/cbdd.l2095.
92. Rominger, D.H., Cowan, C.L., Gowen-Macdonald, W., and Violin, J.D. (2014). Biased ligands: pathway validation for novel GPCR therapeutics. Curr Opin Pharmacol 16, 108-115. doi: 10.1016/j.coph.2014.04.002 S1471-4892(14)00041-l [pii].
93. Rosenbaum, D.M., Cherezov, V., Hanson, M.A., Rasmussen, S.G., Thian, F.S., Kobilka, T.S., Choi, H.J., Yao, X.J., Weis, W.I., Stevens, R.C., and Kobilka, B.K. (2007). GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function. Science (New York, N Y) 318,1266-1273. doi: 10.1126/science.ll50609.
94. Sabio, M., Jones, K., and Topiol, S. (2008). Use of the X-ray structure of the beta2-adrenergic receptor for drug discovery. Part 2: Identification of active compounds. Bioorg Med Chem Lett 18, 5391-5395. doi: 10.1016/j.bmcl.2008.09.046
95. Saito, Y., and Berk, B.C. (2001). Transactivation: a novel signaling pathway from angiotensin II to tyrosine kinase receptors./Mol Cell Cardiol 33, 3-7. doi: 10.1006/jmcc.2000.1272 S0022-2828(00)91272-0 [pii].
96. Sbai, 0., Monnier, C, Dode, C, Pin, J.P., Hardelin, J.P., and Rondard, P. (2014). Biased signaling through G-protein-coupled PROKR2 receptors harboring missense mutations. FASEBJ 28, 3734-3744. doi: 10.1096/fj.13-243402 fj.13-243402 [pii].
97. Scheerer, P., Park, J.H., Hildebrand, P.W., Kim, Y.J., Krauss, N., Choe, H.W., Hofmann, K.P., and Ernst, O.P. (2008). Crystal structure of opsin in its G-protein-interacting conformation. Nature 455, 497-502. doi: 10.1038/nature07330.
98. Scherrer, G., Imamachi, N., Cao, Y.Q., Contet, C, Mennicken, F., O'donnell, D., Kieffer, B.L., and Basbaum, A.I. (2009). Dissociation of the opioid receptor mechanisms that control mechanical and heat pain. Cell 137,1148-1159. doi: 10.1016/j.cell.2009.04.019.
99. Scholten, D.J., Canals, M., Maussang, D., Roumen, L, Smit, M.J., Wijtmans, M., De Graaf, C, Vischer, H.F., and Leurs, R. (2012). Pharmacological modulation of chemokine receptor function. Br J Pharmacol 165, 1617-1643. doi: lO.llll/j.1476-5381.2011.01551.x.
100. Serrano-Vega, M.J., Magnani, F., Shibata, Y., and Tate, C.G. (2008). Conformational thermostabilization of the betal-adrenergic receptor in a detergent-resistant form. Proc Natl Acad Sci US A 105, 877-882. doi: 10.1073/pnas.0711253105.
101. Shapiro, D.A., Renock, S., Arrington, E., Chiodo, L.A., Liu, L.X., Sibley, D.R., Roth, B.L., and Mailman, R. (2003). Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28, 1400-1411. doi: 10.1038/sj.npp.l300203 1300203 [pii].
102. Shimamura, T., Shiroishi, M., Weyand, S., Tsujimoto, H., Winter, G., Katritch, V., Abagyan, R., Cherezov, V., Liu, W., Han, G.W., Kobayashi, T., Stevens, R.C., and Iwata, S. (2011). Structure of the human histamine HI receptor complex with doxepin. Nature 475, 65-70. doi: 10.1038/naturel0236.
103. Sigalov, A.B. (2012). "Monovalent" ligands that trigger TLR-4 and TCR are not necessarily truly monovalent. Mol Immunol 51, 356-362. doi: 10.1016/j.molimm.2012.03.031 S0161-5890(12)00220-9 [pii].
104. Sinisi, A.A., Asci, R., Bellastella, G., Maione, L., Esposito, D., Elefante, A., De Bellis, A., Bellastella, A., and Iolascon, A. (2008). Homozygous mutation in the prokineticinreceptor2 gene (Val274Asp) presenting as reversible Kallmann syndrome and persistent oligozoospermia: case report. Hum Reprod 23, 2380-2384. doi: 10.1093/humrep/den247 den247 [pii].
105. Siu, F.Y., He, M., De Graaf, C, Han, G.W., Yang, D., Zhang, Z., Zhou, C, Xu, Q., Wacker, D., Joseph, J.S., Liu, W., Lau, J., Cherezov, V., Katritch, V., Wang, M.W., and Stevens, R.C. (2013). Structure of the human glucagon class B G-protein-coupled receptor. Nature 499, 444-449. doi: 10.1038/naturel2393.
106. Soergel, D.G., Subach, R.A., Sadler, B., Connell, J., Marion, A.S., Cowan, C.L., Violin, J.D., and Lark, M.W. (2014). First clinical experience with TRV130: pharmacokinetics and pharmacodynamics in healthy volunteers./Clin Pharmacol 54, 351-357. doi: 10.1002/jcph.207.
107. Sokkar, P., Mohandass, S., and Ramachandran, M. (2011). Multiple templates-based homology modeling enhances structure quality of ATI receptor: validation by molecular dynamics and antagonist docking./Mol Model 17, 1565-1577. doi: 10.1007/s00894-010-0860-z.
108. Szatkowski, C, Vallet, J., Dormishian, M., Messaddeq, N., Valet, P., Boulberdaa, M., Metzger, D., Chambon, P., and Nebigil, C.G. (2013). Prokineticin receptor 1 as a novel suppressor of preadipocyte proliferation and differentiation to control obesity. PLoS One 8, e81175. doi: 10.1371/journal.pone.0081175 PONE-D-13-25805 [pii].
109. Tan, Q., Zhu, Y., Li, J., Chen, Z., Han, G.W., Kufareva, I., Li, T., Ma, L, Fenalti, G., Zhang, W., Xie, X., Yang, H., Jiang, H., Cherezov, V., Liu, H., Stevens, R.C., Zhao, Q., and Wu, B. (2013). Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex. Science 341,1387-1390. doi: 10.1126/science.l241475.
110. Thompson, A.A., Liu, W., Chun, E., Katritch, V., Wu, H., Vardy, E., Huang, X.P., Trapella, C, Guerrini, R., Calo, G., Roth, B.L., Cherezov, V., and Stevens, R.C. (2012). Structure of the nociceptin/orphanin FQ receptor in complex with a peptide mimetic. Nature 485, 395-399. doi: 10.1038/naturell085.
111. Topiol, S., and Sabio, M. (2008). Use of the X-ray structure of the Beta2-adrenergic receptor for drug discovery. Bioorg Med Chem Lett 18, 1598-1602. doi: 10.1016/j.bmcl.2008.01.063.
112. Torres, P.U. (2006). Cinacalcet HC1: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease./Ren Nutr 16, 253-258. doi: 10.1053/j.jrn.2006.04.010.
113. Urban, J.D., Vargas, G.A., Von Zastrow, M., and Mailman, R.B. (2007). Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways. Neuropsychopharmacology 32, 67-77. doi: 10.1038/sj.npp.l301071.
114. Valant, C, May, L.T., Aurelio, L, Chuo, C.H., White, P.J., Baltos, J.A., Sexton, P.M., Scammells, P.J., and Christopoulos, A. (2014). Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist. Proc Natl AcadSci USA 111, 4614-4619. doi: 10.1073/pnas.l320962111.
115. Vallone, D., Picetti, R., and Borrelli, E. (2000). Structure and function of dopamine receptors. Neurosci BiobehavRev 24,125-132. doi: S0149-7634(99)00063-9 [pii].
116. Vass, M., Schmidt, E., Horti, F., and Keseru, G.M. (2014). Virtual fragment screening on GPCRs: a case study on dopamine D3 and histamine H4 receptors. EurJ Med Chem 77, 38-46. doi: 10.1016/j.ejmech.2014.02.034.
117. Vilar, S., Karpiak, J., and Costanzi, S. (2010). Ligand and structure-based models for the prediction of ligand-receptor affinities and virtual screenings: Development and application to the beta(2)-adrenergic receptor. J Comput Chem 31, 707-720. doi: 10.1002/jcc.21346.
118. Violin, J.D., Crombie, A.L., Soergel, D.G., and Lark, M.W. (2014). Biased ligands at G-proteincoupled receptors: promise and progress. Trends Pharmacol Sci 35, 308-316. doi: 10.1016/j.tips.2014.04.007 S0165-6147(14)00069-8 [pii].
119. Violin, J.D., and Lefkowitz, R.J. (2007). Beta-arrestin-biased ligands at seventransmembrane receptors. Trends Pharmacol Sci 28, 416-422. doi: 10.1016/j.tips.2007.06.006.
120. Wacker, D., Wang, C, Katritch, V., Han, G.W., Huang, X.P., Vardy, E., Mccorvy, J.D., Jiang, Y., Chu, M., Siu, F.Y., Liu, W., Xu, H.E., Cherezov, V., Roth, B.L., and Stevens, R.C. (2013). Structural features for functional selectivity at serotonin receptors. Science 340, 615-619. doi: 10.1126/science.l232808.
121. Waldhoer, M., Fong, J., Jones, R.M., Lunzer, M.M., Sharma, S.K., Kostenis, E., Portoghese, P.S., and Whistler, J.L. (2005). A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers. Proc Natl Acad Sci USA 102, 9050-9055. doi: 10.1073/pnas.0501112102.
122. Wang, C, Jiang, Y., Ma, J., Wu, H., Wacker, D., Katritch, V., Han, G.W., Liu, W., Huang, X.P., Vardy, E., Mccorvy, J.D., Gao, X., Zhou, X.E., Melcher, K., Zhang, C, Bai, F., Yang, H., Yang, L., Jiang, H., Roth, B.L., Cherezov, V., Stevens, R.C, and Xu, H.E. (2013a). Structural basis for molecular recognition at serotonin receptors. Science 340, 610-614. doi: 10.1126/science.l232807.
123. Wang, C, Wu, H., Katritch, V., Han, G.W., Huang, X.P., Liu, W., Siu, F.Y., Roth, B.L., Cherezov, V., and Stevens, R.C. (2013b). Structure of the human smoothened receptor bound to an antitumour agent. Nature 497, 338-343. doi: 10.1038/naturel2167.
124. Wang, H., Duffy, R.A., Boykow, G.C., Chackalamannil, S., and Madison, V.S. (2008). Identification of novel cannabinoid CB1 receptor antagonists by using virtual screening with a pharmacophore model./Med Chem 51, 2439-2446. doi: 10.1021/jm701519h.
125. Warne, T., Serrano-Vega, M.J., Baker, J.G., Moukhametzianov, R., Edwards, P.C., Henderson, R., Leslie, A.G., Tate, C.G., and Schertler, G.F. (2008). Structure of a betal-adrenergic G-protein-coupled receptor. Nature 454, 486-491. doi: 10.1038/nature07101.
126. Wei, H., Ahn, S., Shenoy, S.K., Karnik, S.S., Hunyady, L, Luttrell, L.M., and Lefkowitz, R.J. (2003). Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proc Natl Acad Sci USA 100, 10782-10787. doi: 10.1073/pnas.l834556100 1834556100 [pii].
127. Weiss, D.R., Ahn, S., Sassano, M.F., Kleist, A., Zhu, X., Strachan, R., Roth, B.L., Lefkowitz, R.J., and Shoichet, B.K. (2013). Conformation guides molecular efficacy in docking screens of activated beta-2 adrenergic G protein coupled receptor. ACS Chem Biol 8, 1018-1026. doi: 10.1021/cb400103f.
128. Whalen, E.J., Rajagopal, S., and Lefkowitz, R.J. (2011). Therapeutic potential of beta-arrestinand G protein-biased agonists. Trends Mol Med 17, 126-139. doi: 10.1016/j.molmed.2010.11.004 S1471-4914(10)00182-6 [pii].
129. White, J.F., Noinaj, N., Shibata, Y., Love, J., Kloss, B., Xu, F., Gvozdenovic-Jeremic, J., Shah, P., Shiloach, J., Tate, C.G., and Grisshammer, R. (2012). Structure of the agonist-bound neurotensin receptor. Nature 490, 508-513. doi: 10.1038/naturell558.
130. Williams, R., Zhou, Y., Niswender, CM., Luo, Q., Conn, P.J., Lindsley, C.W., and Hopkins, C.R. (2010). Re-exploration of the PHCCC Scaffold: Discovery of Improved Positive Allosteric Modulators of mGluR4. ACS Chem Neurosci 1, 411-419. doi: 10.1021/cn9000318.
131. Wu, B., Chien, E.Y., Mol, CD., Fenalti, G., Liu, W., Katritch, V., Abagyan, R., Brooun, A., Wells, P., Bi, F.C., Hamel, D.J., Kuhn, P., Handel, T.M., Cherezov, V., and Stevens, R.C. (2010). Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 330,1066-1071. doi: 10.1126/science.ll94396.
132. Wu, H., Wacker, D., Mileni, M., Katritch, V., Han, G.W., Vardy, E., Liu, W., Thompson, A.A., Huang, X.P., Carroll, F.I., Mascarella, S.W., Westkaemper, R.B., Mosier, P.D., Roth, B.L., Cherezov, V., and Stevens, R.C. (2012). Structure of the human kappa-opioid receptor in complex with JDTic. Nature 485, 327-332. doi: 10.1038/naturel0939.
133. Xing, R.J., Wang, J., Pan, L., and Cheng, M.S. (2009). A Selective Pharmacophore Model for beta(2)-Adrenoceptor Agonists. Molecules 14, 4486-4496. doi: 10.3390/moleculesl4114486.
134. Yekkirala, A.S., Lunzer, M.M., Mccurdy, C.R., Powers, M.D., Kalyuzhny, A.E., Roerig, S.C., and Portoghese, P.S. (2011). N-naphthoyl-beta-naltrexamine (NNTA), a highly selective and potent activator of mu/kappa-opioid heteromers. Proc Natl Acad Sci USA 108, 5098-5103. doi: 10.1073/pnas.l016277108.
135. Zhang, C, Srinivasan, Y., Arlow, D.H., Fung, J.J., Palmer, D., Zheng, Y., Green, H.F., Pandey, A., Dror, R.O., Shaw, D.E., Weis, W.I., Coughlin, S.R., and Kobilka, B.K. (2012). Highresolution crystal structure of human protease-activated receptor 1. Nature 492, 387-392. doi: 10.1038/naturell701.
136. Zhang, J., Zhang, K., Gao, Z.G., Paoletta, S., Zhang, D., Han, G.W., Li, T., Ma, L, Zhang, W., Muller, C.E., Yang, H., Jiang, H., Cherezov, V., Katritch, V., Jacobson, K.A., Stevens, R.C, Wu, B., and Zhao, Q. (2014). Agonist-bound structure of the human P2Y12 receptor. Nature 509,119-122. doi: 10.1038/naturel3288.
137. Zhang, Y., Gilliam, A., Maitra, R., Damaj, M.I., Tajuba, J.M., Seltzman, H.H., and Thomas, B.F. (2010). Synthesis and biological evaluation of bivalent ligands for the cannabinoid 1 receptor. J Med Chem 53, 7048-7060. doi: 10.1021/jml006676